TBI-1501

TBI-1501 is a CAR-T cell therapy developed by Takara Bio. Its target is CD19. ClinicalTrials.gov describes the intervention as: Phase-I portion: Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg). Phase-II portion: Recommended dose of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT03155191, plans to enrol 21 participants with primary completion expected 2035-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.